key: cord-0880116-br3iixiu authors: Mohapatra, Prasanta Raghab; Mishra, Baijayantimala title: BCG Vaccination Policy and Protection Against COVID-19: Correspondence date: 2020-08-11 journal: Indian J Pediatr DOI: 10.1007/s12098-020-03462-1 sha: 61ab63c78b4a74270f652f67e6915151dc6976c1 doc_id: 880116 cord_uid: br3iixiu nan controlled trials of Bacillus Calmette-Guérin vaccination to reduce absenteeism among health care workers and hospital admission by elderly persons during the COVID-19 pandemic: a structured summary of the study protocols for two randomised controlled trials. Trials. 2020;21:481. To the Editor: We appreciate the interest and valuable comments of Mohapatra and Mishra on our article published in IJP [1] . We utilize this opportunity to respond in the best possible way. The analysis by Ozdemir et al. [2] is based on almost three months old data and has all the limitations highlighted by us [1] . The division of countries into two groups based upon the current (2018) BCG vaccination status is inappropriate. Many countries have discontinued BCG vaccination in the last decade itself, and residents of those countries who are more than 10 y of age have been vaccinated in the past but are falsely considered non-vaccinated. Children might be the only population sub-group that did not receive the vaccination in those countries where it has been recently stopped but, they comprise less than 5% of total COVID-19 cases and had very few deaths. The majority of the affected individuals (> 40 y old) in artificially classified non-vaccinated nations, actually received the BCG vaccine in childhood. Therefore, such an analysis based on one-year vaccination coverage is technically wrong. Secondly, the relationship of BCG and COVID-19 in most studies including Ozdemir et al. is oversimplified without adjusting for potential confounders like the difference in population demographics, the prevalence of co-morbidities, number of tests done, different stages of the pandemic in various countries, and variation in health infrastructure [1, 3] . We are aware of ongoing trials of the BCG vaccine in COVID-19 and agree that these trials are based upon the non-specific effects of the BCG vaccine [3] . However, it is inappropriate to equate the recent vaccination within a trial to the childhood vaccination received many decades ago. The existing evidence does not support the persistence of nonspecific immunological effects of the BCG vaccine beyond childhood. In fact, due to the same reason, we should not equate the childhood vaccination policy of a country with the recent vaccination given in the clinical trial. We differ from the authors' comment of Indians having inherent protection from the COVID-19 by the routine childhood BCG vaccination policy. As of now, we stand fourth in the countries with the highest number of cases and probably will ascend in the list with the current case rate. Moreover, among the top four countries with maximum COVID-19 cases, three countries (India, Brazil, and Russia) have more than 90% coverage of the BCG vaccine. BCG vaccination policy and protection against COVID-19 SARS-CoV-2 rates in BCG-vaccinated and unvaccinated young adults Is BCG vaccination affecting the spread and severity of COVID-19? BCG vaccination policy and protection against COVID-19 Is BCG vaccination affecting the spread and severity of COVID-19? Demystifying BCG vaccine and COVID-19 relationship Bacille Calmette-Guérin (BCG) Vaccination and COVID-19 We are also aware of the homology between the SARS-CoV-2 and Yellow fever virus, and the effect of trained immunity of the BCG vaccine over many other viruses. However, it's too early to conclude.These epidemiological associations are prone to biases, and in this rapidly evolving pandemic with frequent changes in data, the conclusions of today may not hold for tomorrow. Therefore, we strongly endorse what World Health Organization states that as of now, there is no evidence of the protective effect of BCG vaccine over COVID-19, and we should wait for the results of the ongoing trials [4].